Skip to content

Effect of Madhumehadaman choorna and phaltrikadi kwath in management of Type 2 Diabetes Mellitus.

A Randomized Clinical Study To Evaluate The Efficacy Of Madhumehadaman Churna and Phaltrikadi Kwatha In The Management Of Madhumeha W.S.R. Type 2 Diabetes Mellitus

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/04/052065
Enrollment
60
Registered
2023-04-27
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

None listed

Sponsors

Ayurvedic and Unani Tibbia College Hospital.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1-Patients of either sex aged between 20-65 years 2-If yes in any two of four : Blood sugar fasting- 125 - 150 mg/dl. PP- 199-250 mg/dl. Glycosylated Haemoglobin (HbA1c) 6.4% - 7.5% Subjects having classical symptoms of diabetes with random glucose levels >=200mg/dl ( 3-Subjects who are able to come for follow up on fixed visits and are well aware about the treatment plan.(only type 2 DM patients) 4-Subjects willing to participate and able to provide written informed consent.

Exclusion criteria

Exclusion criteria: 1-Subject on any other AYUSH medication for glucose control. 2- Patients with type 1 Diabetes Mellitus. 3-Subjects suffering from the complications of Diabetes mellitus viz., diabetic neuropathy, diabetic nephropathy, diabetic retinopathy etc. which require an urgent treatment. 4-Uncontrolled Hypertensive subjects (BP with or without medication >140/90 mmHg after 5 mins of rest). 5-Subjects with any unstable Heart disease or known cases of MI, unstable angina or CHF. 6-Subjects with current or past diagnosis of malignancy (any malignancy diagnosis in last five years). 7-Subjects who have a recent history or who are currently known to abuse of alcohol or drugs. 8-Subjects suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho-Neuro-Endocrinal disorders, TB, AIDS etc). 9-Subjects having hypersensitivity to any of the trial drug. 10- Subjects who have completed participation in any other clinical trial during the past six (06) months. 11- Pregnancy and lactating mothers.

Design outcomes

Primary

MeasureTime frame
Primary outcome would be measured by- Diabetic specific biomarker - HbA1c levels.Timepoint: At baseline and after 12 weeks

Secondary

MeasureTime frame
Assessment will be done clinically on basis of improvement in objective. parameters like 1. Blood sugar fasting ( in mg/dl) 2. Blood sugar post prandial ( in mg/dl). Improvement in subjective parameter. 1. Prabhoota mootrata â?? Polyurea (excessive urine) 2. Avila mootrata â?? Unclear / turbid urine 3. Kshudhaadhikya -Polyphagia( excessive hunger) 4. Pipasaadhikya -Polydipsia (excessive thirst) 5. Daurbalya/Shram- Exhaustion / tiredness 6. Suptaangta/Daha -Polyneuritis (numbness / tingling/ burning of soles) 7. Pindikodveshtana - Cramps while walking/calf muscle pain 8. Vibandh- constipation 9. Swedadikya 10. Swapna sukha.Timepoint: At baseline and after 12 weeks.

Countries

India

Contacts

Public ContactDr SUJATA YADAV

Ayurvedic and Unani Tibbia college Karolbagh, Delhi.

sujatakcdelhi@gmail.com9354925030

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026